Free, self-directed programs for continuing education credit.
Indications for Germline Testing after Genomic Tumor Testing
Learn how to interpret genomic test results to identify patients with hereditary risks.
Access CME Module | Access CNE Module
Choosing the Best Genomic Tumor Test
Learn about the benefits and limitations of different genomic tumor test options for patients with cancer and how to determine the best test for each patient.
Access CME Module | Access CNE Module
Exploring Somatic Cancer Panel Testing
Learn about benefits, limitations, and challenges of using large somatic cancer panels.
Access CME Module | Access CNE Module
Interpreting Results from Somatic Cancer Panel
Practice interpreting cancer genetic testing results and reports within a patient-specific context.
Access CME Module | Access CNE Module
Hereditary Cancer Syndromes: Are your Patients at Risk? Develop skills and knowledge to identify those patients most appropriate for genetic testing, choosing the right test, and using the results to develop a management plan.
Access CME Module | Access CNE Module
Genomic (Somatic) Tumor Testing
Multidisciplinary Expert Insights: Assessing Hereditary Cancer Risks for Genomic Tumor Testing. A multidisciplinary panel of clinical and laboratory experts discusses a case that highlights factors relevant for the interpretation of tumor results for hereditary risks.
How to Maximize the Genomic Tumor Board Experience. Suggests ways for you to make the most of the genomic tumor board experience.
Frequently Asked Questions: Large scale genomic tumor testing. Describes large-scale genomic tumor testing and discusses its benefits, risks, and limitations.
Indications for Germline Testing in Cancer Patients. Identifies genetic red flags to inform personal and family history risk assessment and genomic tumor test results that are suggestive of a germline variant.
Testing to Identify Genomic Variants Related to Cancer. Defines and compares benefits and limitations of type of testing: somatic, paired somatic/germline and concurrent somatic + germline.
Liquid Biopsy FAQ. Describes the benefits, risks and limitations of liquid biopsy.
Anatomy of Genomic Tumor Test Report. Annotated genomic tumor test report.
Comparing Somatic Cancer Panels. Provides information about how somatic tumor test offerings may differ among laboratories.
Assessing Genomic Variants for Targeted Therapy Options. Provides a framework for assessing the evidence supporting targeted treatment options.
Frequently Asked Questions: PARP Inhibition Therapy. Provides an overview of PARP inhibition (PARPi) therapy.
PARP Inhibitors: Overview and Indications. Discusses FDA-approved indications for PARPi for maintenance therapy and cancer treatment as well as emerging uses under investigation.
Evaluating Immune Checkpoint Inhibition Biomarkers. Provides an overview of the benefits and limitations of commonly used immune checkpoint inhibition biomarkers.
Ordering and Interpreting PD-L1 Testing. Discusses which patients may benefit from PD-L1 testing and how to select and interpret tests for patients with different cancer types.
Communicating with Patients
Facilitating shared decision making about somatic tumor testing. Supports clinicians when communicating about the process, benefits, and limitations associated with somatic tumor testing.
Three things to know about direct-to-consumer breast cancer genetic testing
Questions to ask about genomic tumor testing
Communicating with patients about somatic tumor testing
Immunotherapy - implications for patients with mismatch repair deficiency